Study of IBI363 in Patients with Advanced First-line Gastric Cancer

This study is testing a new combination cancer treatment called IBI363 as a first-line therapy for patients with advanced or metastatic gastric cancer (stomach or stomach-esophagus junction cancer) that has not been previously treated. IBI363 is an immunotherapy drug designed to help the immune system fight cancer. This is an early-stage trial evaluating safety and initial effectiveness. **You may be eligible if...** - You are between 18 and 75 years old - You have unresectable advanced or metastatic gastric or gastroesophageal junction cancer - You have not received any prior systemic treatment for this cancer - You have at least one measurable tumor on scans - You are in good general health (ECOG 0–1) with an expected survival of at least 3 months **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active uncontrolled bleeding - Your cancer has spread to the brain or spinal fluid - You have a history of seizures Talk to your doctor to see if this trial is right for you.